

## First transnational call for research projects within the JPIAMR

---

### InnovaResistance: Innovative approaches to address antibacterial resistance

Only transnational projects will be funded. Each proposal must involve a minimum of three (3) countries participating in this call and a maximum of six (6) project participants. Project partners from countries non-participating in the call may be involved in projects if they secure their own funding and if their expertise is indispensable for reaching the objectives. The consortia should always consist of a majority of funded project partners. However, the maximum number of six participants may not be exceeded. Project partners from countries not participating in the call cannot be consortium coordinators and must accept all JPIAMR rules and guidelines just as funded members. Each consortium is encouraged to include participants from academia; clinical/public health and industry (please note the national/regional regulations). Funding will be granted for a maximum of three years. Submissions of proposals will be in two steps: The deadline for submitting pre-proposals is **March 14, 2013** and invited full proposals must be submitted by **July 0X, 2013**. Projects will be expected to start at the **end of 2013 or beginning of 2014**.

#### 1. Aim of the call:

The primary aim of this first joint call of JPIAMR is to combine the resources, infrastructures, and research strengths of multiple countries in order to overcome antibiotic resistance. The goal is to foster multinational translational research collaborations that can accomplish more than individual countries working independently, leading to improved control of bacterial infections.

##### 1.1 Call Topics:

The call will cover research addressing the two following topics:

- Re-evaluation of existing anti-microbial compounds either alone or in combination with other drugs, immune-modulators or anti-bacterial approaches.
- Identification of new bacterial targets and/or therapeutic compounds in combination with point-of-care companion diagnostics where relevant.
- Discovery and implementation of novel therapies to overcome known antimicrobial resistance mechanisms and restore susceptibility to conventional antibiotics. Examples might include studies on novel enzyme or efflux pump inhibitors, as well as studies aimed at understanding and overcoming the mechanisms controlling the generation of resistance.
- Strategies for optimization of drug use, dosage and delivery of new drugs or drug combinations.

- Strategies to inhibit or reduce the acquisition of resistance such as single molecular agents effective against multiple targets as well as therapeutics that enhance immune pathogen elimination, disrupt colonization, biofilm development, and virulence.

### **Excluded sub-topics:**

Following topics which directly address the cross-talk between host and pathogens, as well as the relationship between microbes' environment and infection are excluded. Particularly:

- Assessing the role of commensal flora in homeostasis and microbe's pathogenicity, and elucidating how commensal organisms or probiotics can be used to prevent or treat infections.
- Investigating the initial steps of the infection process.
- Not supporting late stage clinical trials.

### **1.2 Justification:**

The dearth of new bactericidal or bacteriostatic drugs entering the clinic and the emergence of infections due to multi-antibiotic resistant bacteria requires international collaboration supported by substantial financial investment. New drugs and/or therapeutic approaches are urgently needed to control bacterial infections and safeguard the health of populations.

### **1.3 Expected Impact:**

It is expected that through international collaborations that combine complementary and synergistic research strengths, this JPIAMR call will facilitate the generation and application of new approaches to overcome antibiotic resistance. Proposals are expected to clearly define described targets and milestones to deliver clinically relevant outcomes within the funding period.

## **2. Application:**

### **2.1 Eligibility**

Applicants must adhere to the specific regulations of the national funding organisations. Each transnational consortium submitting a proposal must involve:

- a minimum of three (3) countries
- a maximum of six (6) countries/project participants
- Project partners (including industrial, clinical partners) from countries non-participating in the call may be involved in projects if they secure their own funding and if their expertise is

indispensable for reaching the objectives. The consortia should always consist of a majority of funded project partners.

- Project partners from countries not participating in the call cannot be consortium coordinators and must accept all JPIAMR rules and guidelines just as funded members.
- Each consortium should encourage participation from academia and clinics and industry (please note the national regulations).

## 2.2 Submission of joint transnational proposal

Submissions of proposals will be in two steps. In both cases, one joint proposal document (in English) shall be prepared by the project partners of a joint transnational proposal, and must be submitted to the Joint Call Secretariat by the coordinator. A submission tool will be implemented in the JPIAMR website ([www.submission-JPIAMR.eu](http://www.submission-JPIAMR.eu)). For details see also the **Guidelines for Applicants**.

The two-steps application process (pre-proposal, full proposal) will have the following timetable:

January 27 <sup>th</sup> , 2014	<b>Publication of the JPIAMR Joint Transnational Call with Canada</b>
March 14 <sup>th</sup> , 2014 (17:00 CET)	<b>Submission deadline for pre-proposals</b>
Mid May 2014	<b>PRP Sub group meeting</b>
Late May 2014	<b>Decision on full proposal invitation by CSG</b>
Late May 2014	<b>Full proposal invitations send to project coordinators</b>
July 21 <sup>st</sup> , 2014 (17:00 CET)	<b>Submission deadline for full proposals</b>
September 18 <sup>th</sup> , 2014	<b>PRP meeting, final ranking, CSG meeting</b>
By October 15 <sup>th</sup> , 2014	<b>Final funding decision</b>
End of 2014/Early 2015	<b>Start of funding</b>

## 2.3 Financial modalities and funding prerequisites

Funding is granted for a maximum of three years in accordance with national regulations. **Applicants must refer and adhere to their own specific national regulations and scientific remits as detailed in the National Announcements.** Clarification may be obtained from the individual funding agencies (see contact details below).

The funds provided by the Parties are listed in the table below. The “virtual common pot model” shall apply for this transnational call. As such, each country will fund its own approved project partners. The proposals will be funded, as far as possible, following the ranking list recommended by the Peer Review Panel.

### Anticipated funding provided by each party

Name of Organisation	Country	Contribution in million €
FWO	Belgium	0,15
CIHR	Canada	4.1
The Danish Council for Strategic Research	Denmark	0,5
Agence Nationale de la Recherche	France	1
Federal Ministry of Education and Research	Germany	1,5
Chief Scientist Office, Ministry of Health	Israel	0,24
ZonMw	Netherlands	1
The Research Council of Norway (RCN)	Norway	0,5
	Poland	0,25
Ministry of National Education-RO	Romania	0,3
National Institute of Health Carlos III (ISCIII)	Spain	0,2
Swedish Research Council	Sweden	2
MRC	United Kingdom	1,19
	<i>Turkey</i>	<i>?</i>

Each consortium should provide a consortium agreement (CA) signed by all participants. The project consortium is strongly encouraged to sign this CA before the start of the project to clarify the potential IPR matters (such as licensing in, licensing out, patent and exploitation strategy), and in any case the no later than six months after the official project start date. The points that must be addressed in the CA are detailed in the Annex C.

### **2.4 Contact persons**

The only official communication line of the proposal is between the Joint Call Secretariat and the project coordinator. The project coordinator will be the person contacted by the Joint Call Secretariat during the application procedure, so he/she must forward this information to the other participants. Each funding organization has national contact persons who can be contacted for information about the specific national requirements (see table below).

<b>Country</b>	<b>Funding org.</b>	<b>Contact person</b>	<b>Email</b>
Belgium	IWT		
Canada	CIHR	Judith Bray	Judith.bray@cihr-irsc.gc.ca
Denmark	DASTI	Peder Fode	pff@fi.dk
France	ANR	Dr. Serawit Bruck	Serawit.bruck@agencerecherche.fr
Germany	BMBF/PtJ	Dr. Henrike Knizia	h.knizia@fz-juelich.de
Israel	CSO-MOH	Dr. Benny Leshem	benny.leshem@moh.health.gov.il
Netherlands	ZonMw	Dunja Dreesens	dreesens@zonmw.nl
Norway	RCN	Sonja Prehn Dyveke Hetland	<a href="mailto:sp@forskningsradet.no">sp@forskningsradet.no</a> <a href="mailto:dhe@forskningsradet.no">dhe@forskningsradet.no</a>
Poland	NCN		
Poland	NCBR		
Romania	MEN		
Spain	ISCIII	Dr. Gloria Villar Acevedo	gvillar@isciii.es
Sweden	SRC	Dr. Pontus Holm	Pontus.Holm@vr.se
UK	MRC	Dr Ghada Zoubiane	Ghada.zoubiane@headoffice.mrc.ac.uk
Turkey	TUBITAK		

### Summary of funding and restriction (I)

Funding Body/ Country	CIHR (CA)	FWO (BE)	DASTI (DK)	ANR (FR)	BMBF (DE)	CSO-MOH (IL)
<b>Funding of industrial partners eligible?</b>	No	No	Yes	Yes	Yes	Only on their own funding
<b>Participation of industry required?</b>	No	No	No	No	No	
<b>Maximum funding per partner/ per project</b>	TBD	200.000 EUR /1 project/ max. 4 years	No	No; the request depends on the scientific need and justification for the budget. Minimum amount per partner: 15 000 €.	No	60 Keuro
<b>Eligible costs</b>	Regular CIHR policies will apply	ref. National Regulations	See national guidelines	Personnel, Consumables, Animals, Subcontracts (if costs-<50% eligible costs), Equipment, Travel. See French Annex for details	See national guidelines	Personnel (not for applicants), animals, consumables, animals, travel (see limits), 10% overhead
<b>Additional documents required</b>	No	No	See national guidelines	No	No	
<b>Other national restrictions</b>	No indirect Costs will be covered	ref. National Regulations	See national guidelines	For projects selected for funding: - National budget request forms - A copy of the signed consortium agreement established between the consortium partners must be provided to ANR before the first payment to the French	See national guidelines	Applicants with pending or funded CSO-MOH projects are ineligible

### Summary of funding and restriction (II)

Funding Body/ Country	MRC (UK)	ZonMw (NL)	Poland	(RCN), Norway	MEN Romania	ISCIII (E)	SRC (SW)
<b>Funding of industrial partners eligible? Participation of industry required?</b>	No No	Please consult <a href="http://www.zonmw.nl/nl/subsidies/voorwaarden-en-financien/">http://www.zonmw.nl/nl/subsidies/voorwaarden-en-financien/</a> or your national contact person		No		No	
<b>Maximum funding per partner/ per project</b>	No			0.250 Mio € per year		Up to 150.000 for coordinators. Up to 75.000 for non-coordinators	
<b>Eligible costs</b>	Follow MRC guidance	Please consult <a href="http://www.zonmw.nl/nl/subsidies/voorwaarden-en-financien/">http://www.zonmw.nl/nl/subsidies/voorwaarden-en-financien/</a> or your national contact person		0.5 Mio € per year		See national guidelines	
<b>Additional documents required</b>	No	Please consult <a href="http://www.zonmw.nl/nl/subsidies/voorwaarden-en-financien/">http://www.zonmw.nl/nl/subsidies/voorwaarden-en-financien/</a> or your national contact person		No		No	
<b>Other national restrictions</b>	Follow MRC guidance	Please consult <a href="http://www.zonmw.nl/nl/subsidies/voorwaarden-en-financien/">http://www.zonmw.nl/nl/subsidies/voorwaarden-en-financien/</a> or your national contact person		No		See national guidelines	